Latigo reports Q3 2026 results, names new CEO, adds opioid arm to Phase 3 trial
Latigo said its Phase 3 bunionectomy and safety trials of onzotrigine remain on track for 2027 topline data as Todd Smith succeeds Nima Farzan as CEO.
SEC filing (2)
2 stories
Latigo said its Phase 3 bunionectomy and safety trials of onzotrigine remain on track for 2027 topline data as Todd Smith succeeds Nima Farzan as CEO.
SEC filing (2)
Latigo said its Phase 3 program for onzotrigine will start in the second half of 2026, with cash it says funds operations into 2029.
SEC filing